comparemela.com

Latest Breaking News On - Rock springs capital management - Page 9 : comparemela.com

Piper Sandler Lowers Aeglea BioTherapeutics (NASDAQ:AGLE) to Neutral

Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) was downgraded by analysts at Piper Sandler from an “overweight” rating to a “neutral” rating in a report released on Thursday, The Fly reports. They currently have a $1.00 target price on the biotechnology company’s stock, down from their prior target price of $4.00. Piper Sandler’s price objective points […]

$146 27 Million in Sales Expected for Freshpet, Inc (NASDAQ:FRPT) This Quarter

Analysts expect Freshpet, Inc. (NASDAQ:FRPT – Get Rating) to report $146.27 million in sales for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Freshpet’s earnings, with the lowest sales estimate coming in at $145.18 million and the highest estimate coming in at $147.20 million. Freshpet reported sales of $108.62 […]

Covetrus, Inc (NASDAQ:CVET) Holdings Increased by Strs Ohio

Strs Ohio grew its stake in shares of Covetrus, Inc. (NASDAQ:CVET – Get Rating) by 3,916.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,100 shares of the company’s stock after buying an additional 23,500 shares during the quarter. Strs Ohio’s holdings in […]

Brokerages Set Phreesia, Inc (NYSE:PHR) Target Price at $64 15

Phreesia, Inc. (NYSE:PHR – Get Rating) has received an average rating of “Buy” from the sixteen research firms that are currently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month target price among brokers that […]

Brokerages Expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to Announce -$1 73 EPS

Equities analysts expect that Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) will post earnings of ($1.73) per share for the current quarter, according to Zacks Investment Research. Nine analysts have made estimates for Ultragenyx Pharmaceutical’s earnings, with estimates ranging from ($2.21) to ($1.46). Ultragenyx Pharmaceutical reported earnings of ($2.03) per share in the same quarter […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.